Flu Hospitalization Rate Week 21: Market Locks In

The flu surveillance calendar is almost done for Week 21, 2026. The CDC tracks weekly influenza-associated hospitalization rates through its FluSurv-NET system, and by late May, hospitalization rates historically compress as flu season winds down. The market has already priced the 85-to-90 range as the most likely outcome, sitting at 86.5% implied probability with resolution arriving June 5.

The market question asks which hospitalization rate band will be confirmed for Week 21 of 2026. The 85-90 bracket carries a YES price of $0.87. Competing outcomes include the 80-85 range, the 90-95 range, and brackets below 80 or above 100. Total volume stands at $1,001, with the full $1,001 trading in the last 24 hours. Liquidity in the order book sits at $2,887.

How the Week 21 Hospitalization Rate Contract Works

This contract resolves YES if the CDC’s confirmed influenza-associated hospitalization rate for Week 21, 2026 falls within the 85-to-90 range per 100,000 population. The CDC’s FluSurv-NET system provides the authoritative data. Resolution is set for June 5, 2026, at 4:00 PM ET.

• YES ($0.87, 86.5% implied): CDC Week 21 rate lands between 85 and 90 per 100,000.
• NO ($0.14, 13.5% implied): CDC Week 21 rate falls outside that band, into any adjacent bracket.

For the contract to pay NO, the Week 21 rate would need to miss the 85-90 window entirely. That means either a sharper-than-expected late-season drop pushing the rate below 85, or a surprising uptick carrying it above 90. Late May historically sees rates declining or plateauing, making a sudden upward move unusual. A drop below 80 would represent an atypically steep week-over-week decline at this point in the season.

Sponsored Partner

Momentum and Market Signals

Momentum here tells a clear story. The trend score sits at 34.51, with the one-hour price change flat at zero and the 24-hour change showing the market opened at $0.29 and surged to $0.87 on June 1. That kind of single-day move, more than 50 cents, reflects a data-driven repricing event, almost certainly tied to updated CDC surveillance figures becoming available. When hospitalization data dropped and landed in or near the 85-90 band, traders moved fast.

Volume is thin. At $1,001 total, with all of it trading in the last 24 hours, this is a micro-liquidity market. The $2,887 order book provides some cushion, but a single large bet could move this price meaningfully before June 5. Thin markets like this one amplify any late CDC data revision or unexpected surveillance report.

• The one-hour and 24-hour momentum composite points strongly bullish, driven by the June 1 repricing off new CDC data.
• Total volume of $1,001 flags this as a low-liquidity contract where price is sensitive to new information.
• The 30-day low of $0.29 confirms that before this week, traders were far less certain about which band would win.
• Trader sentiment is strongly bullish: 86.5% YES versus 13.5% NO.
• No whale trades are present, so the June 1 move came from smaller participants responding to the same CDC release.

Lines Analysis: CDC Data and the Band That Fits

The data doesn’t care about the politics, and here the data has spoken with unusual clarity. Week 21 hospitalization figures appear to have emerged in a range that fits the 85-90 bracket. The market moved from deep uncertainty ($0.29) to high conviction ($0.87) in a single session. That kind of jump doesn’t happen without a concrete data anchor. FluSurv-NET publishes weekly, and June 1 aligns with a typical CDC release window for prior-week surveillance data.

What makes NO real is narrower than the price suggests, but it isn’t zero. The CDC occasionally revises preliminary hospitalization figures upward or downward in subsequent weekly publications. A revision pushing the rate above 90 or below 85 before June 5 would flip this contract. The 90-95 bracket is the most plausible alternative if late-season hospitalization activity surprised to the upside in any of the FluSurv-NET catchment areas. The market is assigning that scenario roughly 13.5% combined probability across all non-85-90 outcomes.

• CDC FluSurv-NET publishes revised Week 21 figures: any upward revision above 90 or downward revision below 85 reprices this contract before June 5.
• An unexpected regional flu surge in Week 21 data would favor the 90-95 bracket and challenge current pricing.
• A steeper late-season decline than the current data reflects would push the rate below 85, benefiting the 80-85 or below-80 brackets.
• No CDC policy change or methodology revision is currently flagged that would affect how Week 21 rates are calculated.

Here’s what the measurements are telling us: a rate in the 85-90 range for late May is consistent with historical flu season trajectories, where Week 21 typically represents a declining but still measurable hospitalization burden. With $1,001 in total volume, this market is pricing uncertainty rather than deep scientific disagreement. The 86.5% probability reflects a specific data point already in the pipeline, not a broad consensus forecast. The question before June 5 is whether that preliminary figure holds through any CDC revision cycle.

LINES VERDICT

High Conviction, Thin Market

The June 1 repricing from $0.29 to $0.87 reflects a specific CDC data release landing in the 85-90 band, and the market has responded accordingly. The remaining uncertainty lives in the revision window before June 5, not in a fundamental disagreement about flu season trajectory.

What the market says: At 86.5% implied probability, this contract is treated as near-settled. The market is pricing uncertainty, not science. Volume this thin means any CDC revision in the next four days could produce a price swing that the current order book absorbs awkwardly.

Key unknown: The single most important event before June 5 is whether the CDC issues any revision to its preliminary Week 21 FluSurv-NET hospitalization figures. A revision moving the rate outside the 85-90 band is the only mechanism that reprices this contract materially.